ストックスクリーナーアプリを入手
1.4099
10.55%
0.1299
前日終値:
$1.28
開ける：
$1.3
24時間の取引高:
136.00K
Relative Volume:
0.29
時価総額：
$104.45M
収益：
-
当期純損益:
$-21.65M
株価収益率:
-4.0157
EPS:
-0.3511
ネットキャッシュフロー:
$-15.84M
1週間 パフォーマンス:
+7.20%
1か月 パフォーマンス:
-9.87%
6か月 パフォーマンス:
-27.81%
1年 パフォーマンス:
+60.80%
1日の値動き範囲:
$1.30
$1.4299
1週間の範囲:
$1.23
$1.4299
52週間の値動き範囲:
$0.8711
$3.12
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
CRDL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.4099 | 104.45M | 0 | -21.65M | -15.84M | -0.3321 |
|
ZTS
Zoetis Inc
|
164.45 | 73.51B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.515 | 43.13B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.27 | 41.98B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.09 | 24.97B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.54 | 14.86B | 15.05B | -883.30M | 1.89B | -0.74 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-26 | 開始されました | ROTH MKM | Buy |
| 2024-04-22 | 開始されました | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc (CRDL) 最新ニュース
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Short Interest Up 12.4% in December - MarketBeat
Appendix 3Y x4 - Investing News Network
Cardiol Therapeutics Sees Insider Buying From Leadership Team And Board Members - The Deep Dive
Guillermo Torre Purchases 17,240 Shares of Cardiol Therapeutics Inc. (TSE:CRDL) Stock - MarketBeat
Insider Buying: Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Buys 18,900 Shares of Stock - MarketBeat
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases - Proactive financial news
HC Wainwright Has Positive Forecast for CRDL FY2024 Earnings - Defense World
FY2024 Earnings Forecast for CRDL Issued By HC Wainwright - MarketBeat
RAD 202 receives approval to start Phase 1 therapeutic trial - Investing News Network
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis - The Manila Times
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis - Investing News Network
PRISM MarketView Features Q&A with President and CEO David - GlobeNewswire
HC Wainwright Reiterates Buy Rating for Cardiol Therapeutics (NASDAQ:CRDL) - MarketBeat
Cardiex Completes Placement Ahead of CONNEQT US Launch - Investing News Network
BPH Global receives funding commitment of A$100,000 - Investing News Network
Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Bernard Lim Acquires 10,000 Shares of Stock - MarketBeat
David Elsley Buys 40,000 Shares of Cardiol Therapeutics Inc. (TSE:CRDL) Stock - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Trading Down 2.1%What's Next? - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Trading Down 2.1% – Here’s What Happened - Defense World
Townsquare Capital LLC Buys New Shares in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
Cardiol Therapeutics (STU:CT9) Momentum Rank : 6 (As of Dec. 05, 2024) - GuruFocus.com
Cardiol Therapeutics (OTCMKTS:CRTPF) Shares Down 3.1% – Should You Sell? - Defense World
Cardiol Therapeutics (TSX:CRDL) Price-to-Operating-Cash-Flo - GuruFocus.com
CRDL (Cardiol Therapeutics) 50-Day SMA : $1.88 (As of Dec. 01, 2024) - GuruFocus.com
Cardiol Therapeutics (TSX:CRDL) Enterprise Value : C$168.30 Mil (As of Dec. 01, 2024) - GuruFocus.com
Cardiol Therapeutics (FRA:CT9) Price-to-Free-Cash-Flow : N/A (As of Dec. 01, 2024) - GuruFocus.com
3 Penny Stocks Ready to Break Out in 2025 - MarketBeat
3 Penny Stocks Ready To Break Out In 2025 - Barchart
Cardiol Therapeutics (CRDL-Q) QuotePress Release - The Globe and Mail
Cardiol Therapeutics (FRA:CT9) Cyclically Adjusted Revenue per Share : €0.00 (As of Sep. 2024) - GuruFocus.com
Game-Changing Solution for Heart Inflammation? | David Elsley – Cardiol Therapeutics - The Deep Dive
HC Wainwright Issues Optimistic Estimate for CRDL Earnings - Defense World
Comparing Cardiol Therapeutics (NASDAQ:CRDL) & Gilead Sciences (NASDAQ:GILD) - Defense World
What is HC Wainwright's Forecast for CRDL FY2024 Earnings? - MarketBeat
Equities Analysts Set Expectations for CRDL FY2024 Earnings - Defense World
Cardiol Therapeutics (NASDAQ:CRDL) Earns Buy Rating from HC Wainwright - Defense World
Cardiol Therapeutics (TSE:CRDL) Shares Up 1.8%What's Next? - MarketBeat
Leede Financial Issues Positive Forecast for CRDL Earnings - Defense World
Cardiol Therapeutics (Nasdaq: CRDL) Advances Orphan Drug - openPR
What is Leede Financial’s Estimate for CRDL FY2027 Earnings? - Defense World
What is Leede Financial's Forecast for CRDL FY2024 Earnings? - MarketBeat
Roth Capital Has Negative Outlook for CRDL FY2024 Earnings - MarketBeat
Biotech Initiates Phase III Trial for Heart Disease Drug - Streetwise Reports
Pericarditis Drugs Market Is Expected To Reach $816.6 Million - openPR
Cardiol Therapeutics (NASDAQ:CRDL) Given Buy Rating at HC Wainwright - MarketBeat
What is Leede Financial's Forecast for CRDL FY2027 Earnings? - MarketBeat
CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study - Benzinga
Analyst Says Biotech's Data Supports Advancement Into Phase III - Streetwise Reports
Five Top Heart Health Stocks to Buy Heading into 2025 - Baystreet.ca
Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLMA Must-Watch This Week! - openPR
Cardiol Therapeutics Inc. - Baystreet.ca
Cardiol Therapeutics Inc (CRDL) 財務データ
収益
当期純利益
現金流量
EPS
1.52%
0.22%
大文字化:
|
ボリューム (24 時間):